Data protection Impressum

Biotech

WuXi AppTec has opened a new pharmaceutical production line at its site in Couvet, in the canton of Neuchâtel. The USD 100 million investment is part of a broader project to make the site a main production center in Europe for the group.

WuXi AppTec inaugurates a USD 100 million spray-drying line in Couvet

7 October 2026

A new study by BAK Economics shows that the life sciences sector generates CHF 20.6 billion in direct value added in Western Switzerland, and CHF 28.3 billion once its ripple effects across the regional economy are taken into account.

Life sciences generate CHF 28.3 billion in direct value in Western Switzerland

6 October 2026

FluoSphera, the Geneva-based biotech developing advanced in vitro models, has entered a license agreement for Debiopharm's AbYlink antibody conjugation technology, combining it with light sheet microscopy from Leica Microsystems into a single workflow for antibody characterization.

FluoSphera partners with Debiopharm and Leica Microsystems

7 September 2026

Addex Therapeutics, the Geneva-based clinical-stage biotech developing small-molecule allosteric modulators for neurological disorders, has raised gross proceeds of USD 2.8 million through its at-the-market program.

Addex Therapeutics extends its cash runway into the fourth quarter of 2027

31 August 2026

Adaptyv Biosystems has closed a USD 40 million Series A round to expand the automated laboratory it operates for the rapid experimental validation of newly designed proteins.

Adaptyv raises USD 40 million for its automated protein lab

31 August 2026

Oculis, the Lausanne-based biopharmaceutical company focused on ophthalmology and neuro-ophthalmology, will acquire all worldwide development and commercial rights to Privosegtor from Accure, terminating its existing license agreement.

Oculis acquires worldwide rights to its Privosegtor candidate

17 August 2026

AB2 Bio has received a USD 30 million payment after Japanese pharmaceutical company Nippon Shinyaku exercised its option to commercialize Tadekinig alfa in the United States, with up to USD 600 million in further milestone and royalty payments.

AB2 Bio receives USD 30 million as Nippon Shinyaku takes up US rights

3 August 2026

Immitra Bio, based in Plan-les-Ouates in the canton of Geneva, has closed an upsized CHF 2.4 million pre-seed round to advance its scalable in-vivo gene editing platform and its lead candidate for an inherited anemia.

Immitra Bio raises CHF 2.4 million to advance its in-vivo gene editing platform

3 August 2026

Pilatus Biosciences, a Biopôle-based biotech whose lead therapy originated in research conducted in Lausanne, has established a subsidiary in Hong Kong and received regulatory approval to begin a clinical trial of PLT012 in patients with advanced solid tumors.

Pilatus Biosciences takes its Lausanne-born immunotherapy to Hong Kong

3 August 2026

AC Immune will receive a USD 4 million research grant from The Vijay and Marie Goradia Charitable Foundation to extend Part 1 of the Phase 2 VacSYn trial of ACI-7104, its immunotherapy for early Parkinson's disease.

AC Immune secures USD 4 million grant to advance its Parkinson’s immunotherapy

6 July 2026

1 2 3 4 5 … 19